Rona Therapeutics Secures $25M Pre-B Round to Advance siRNA Therapies

Shanghai-based Rona Therapeutics announced the successful completion of a $25 million (RMB 180 million) Pre-B financing round. This funding will accelerate the development of the company’s proprietary delivery and chemical modification platform technologies and expand its siRNA clinical pipeline in cardiovascular metabolic, weight loss, and other therapeutic areas.

Investor Support and Confidence
The round was led by Guanghua Wutong, with participation from Lilly Asia Ventures, LongRiver Investments, BioTrack Capital, and other new and existing investors. This support underscores the confidence in Rona Therapeutics’ innovation in the nucleic acid drug space.

Funding Utilization
Proceeds from this financing will be used to advance Rona Therapeutics’ clinical studies, deepen the research and development of extrahepatic systemic drug delivery platform, and enhance its large-scale production capabilities. The company has made significant progress in clinical pipeline advancement and preclinical research, validating its platform’s technical advantages and clinical potential.

Strategic Vision
Since its founding in 2021, Rona Therapeutics has established itself as a leader in siRNA therapeutics through its modular and programmable delivery and chemical modification platforms. The company is committed to addressing complex diseases such as hypercholesterolemia and hypertriglyceridemia. This Pre-B financing will further solidify Rona Therapeutics’ position in the global oligonucleotide drug market.-Fineline Info & Tech